The development of the potential and targeted selective inhibitors for key pathways and the extractive real hub genes, including CDC20, CCNB1, CCNA2, KIF11 and PUF60, may provide a novel treatment opportunity for MCL therapy. Here, KIF11 is linked to mantle cell lymphoma.